The effect of dupilumab on clinical outcomes in patients with COVID-19: A meta-analysis - 23/11/23
Doi : 10.1016/j.jinf.2023.10.015
Toni Li 1
Division of Emergency Medicine, Department of Medicine, University of Toronto, Toronto, Canada
Basma Nasr 1
Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning, China
∗Correspondence to: No.18 Wanxiang North Road, High-tech District, Chengdu 610095, Sichuan, China.No.18 Wanxiang North Road, High-tech DistrictChengduSichuan610095China
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | This meta-analysis included 6 studies and 1972 patients to examine the efficacy of dupilumab for COVID-19 treatment. |
• | Dupilumab significantly reduced the risk of mortality compared to control groups in COVID-19 patients. |
• | In the subgroup analysis of patients with dermatitis was associated with reduced risk of hospitalization. |
© 2023
The British Infection Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 87 - N° 6
P. e107-e109 - décembre 2023 Retour au numéro
Article précédent
- Diagnostic performance of plasma metagenomic next-generation sequencing for infected pancreatic necrosis: A prospective multicenter study
- Dingcheng Shen, Chiayen Lin, Xiaoyue Hong, Jiarong Li, Gengwen Huang
- Targeted next-generation sequencing technology showed great potential in identifying spinal tuberculosis and predicting the drug resistance
- Guang Zhang, Hongqi Zhang, Ye Zhang, Xiaojiang Hu, Mingxing Tang, Qile Gao
Bienvenue sur EM-consulte, la référence des professionnels de santé.